MCID: MXD026
MIFTS: 32

Mixed Glioma malady

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Mixed Glioma

Aliases & Descriptions for Mixed Glioma:

Name: Mixed Glioma 12 52 14
Mixed Gliomas 12 69
Glioma 42 69
Mixed Neuroglial Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5076
MeSH 42 D005910
NCIt 47 C3903
SNOMED-CT 64 22217002 443937008
UMLS 69 C0259783

Summaries for Mixed Glioma

MalaCards based summary : Mixed Glioma, also known as mixed gliomas, is related to adult brainstem mixed glioma and oligoastrocytoma. An important gene associated with Mixed Glioma is GFAP (Glial Fibrillary Acidic Protein), and among its related pathways/superpathways are Photodynamic therapy-induced AP-1 survival signaling. and Central carbon metabolism in cancer. The drugs Gliadel Wafer and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include brain, endothelial and cerebellum.

Related Diseases for Mixed Glioma

Diseases related to Mixed Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 77)
id Related Disease Score Top Affiliating Genes
1 adult brainstem mixed glioma 12.0
2 oligoastrocytoma 11.4
3 anaplastic oligoastrocytoma 10.9
4 mixed oligodendroglioma-astrocytoma 10.9
5 liver fibrosarcoma 10.3 GFAP TP53
6 cervical adenoid cystic carcinoma 10.3 GFAP TP53
7 bronchitis 10.2 GFAP TP53
8 bile duct clear cell adenocarcinoma 10.2 GFAP TP53
9 cervical benign neoplasm 10.2 GFAP TP53
10 vulvar benign neoplasm 10.2 GFAP TP53
11 porokeratosis 10.2 GFAP TP53
12 adult brainstem gliosarcoma 10.2 GFAP TP53
13 blood group incompatibility 10.2 GFAP TP53
14 mast-cell sarcoma 10.2 GFAP TP53
15 olfactory neuroblastoma 10.2 GFAP TP53
16 mixed epithelial stromal tumour 10.2 GFAP TP53
17 pineoblastoma 10.2 GFAP TP53
18 brain stem astrocytic neoplasm 10.2 GFAP TP53
19 childhood choroid plexus cancer 10.2 GFAP TP53
20 arthus reaction 10.2 GFAP TP53
21 pancreatic cancer 10.2 GFAP TP53
22 plasmodium ovale malaria 10.2 GFAP TP53
23 pacinian tumor 10.2 GFAP TP53
24 fragile x-associated tremor/ataxia syndrome 10.2 PDGFRA TP53
25 fallopian tube benign neoplasm 10.2 GFAP TP53
26 clear cell variant infiltrating bladder urothelial carcinoma 10.2 GFAP TP53
27 inner ear cancer 10.2 GFAP TP53
28 mediastinum synovial sarcoma 10.2 PDGFRA TP53
29 pharynx cancer 10.2 GFAP TP53
30 papillary tumor of the pineal region 10.2 GFAP IDH1
31 childhood medulloblastoma 10.2 GFAP TP53
32 bone benign neoplasm 10.1 KIAA1549 TP53
33 testis refractory cancer 10.1 IDH1 TP53
34 adenofibroma 10.1 GFAP IDH1
35 cystinosis, nephropathic 10.1 IDH1 TP53
36 breast squamous cell carcinoma 10.1 GFAP TP53
37 hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 10.1 GFAP IDH1
38 glioma 10.1
39 brain stem angioblastoma 10.1 IDH1 TP53
40 central nervous system hemangioma 10.1 GFAP TP53
41 interstitial lung disease 10.1 GFAP PDGFRA TP53
42 melanotic neurilemmoma 10.1 GFAP IDH1
43 flat ductal epithelial atypia 10.1 GFAP TP53
44 spinal cord astrocytoma 10.1 IDH1 KIAA1549
45 c-p angle neurinoma 10.1 GFAP PDGFRA
46 clear cell meningioma 10.1 GFAP KIAA1549 TP53
47 acinar cell carcinoma 10.1 AGO2 TP53
48 childhood embryonal testis carcinoma 10.0 GFAP IDH1 TP53
49 cutaneous adenocystic carcinoma 10.0 GFAP IDH1 TP53
50 benign ependymoma 10.0 PDGFRA TP53

Graphical network of the top 20 diseases related to Mixed Glioma:



Diseases related to Mixed Glioma

Symptoms & Phenotypes for Mixed Glioma

Drugs & Therapeutics for Mixed Glioma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Gliadel Wafer 17 46 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals Approved February 1997

Drugs for Mixed Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 297)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
2
Cyclophosphamide Approved, Investigational Phase 2, Phase 3, Phase 1, Early Phase 1 50-18-0, 6055-19-2 2907
3
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
4
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
5
Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
6
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
7
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
8
Aminolevulinic acid Approved Phase 3,Phase 2,Phase 1 106-60-5 137
9
Lomustine Approved Phase 3,Phase 1 13010-47-4 3950
10
Procarbazine Approved Phase 3,Phase 2,Phase 1 671-16-9 4915
11
Vincristine Approved, Investigational Phase 3,Phase 1 2068-78-2, 57-22-7 5978
12
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
14
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
15
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
16 Sodium thiosulfate Approved Phase 3,Phase 1,Phase 2
17
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
18
Isotretinoin Approved Phase 3,Phase 1 4759-48-2 5538 5282379
19
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
20
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
21
Ondansetron Approved Phase 3 99614-02-5 4595
22
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
23
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
24
Cyproheptadine Approved Phase 3 129-03-3 2913
25
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
26
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538
27
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
28 Etoposide phosphate Phase 2, Phase 3,Phase 1
29 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
31 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
32 Dermatologic Agents Phase 3,Phase 2,Phase 1
33 Photosensitizing Agents Phase 3,Phase 2,Phase 1
34 Analgesics Phase 3,Phase 2,Phase 1
35 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
36 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
37 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
38 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
39 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antimitotic Agents Phase 3,Phase 1
41 Anesthetics Phase 3,Phase 1
42 Anesthetics, General Phase 3
43 Anesthetics, Inhalation Phase 3
44 Central Nervous System Depressants Phase 3,Phase 2
45 Dihematoporphyrin Ether Phase 3,Phase 2,Phase 1
46 Ether Phase 3,Phase 2,Phase 1
47 Hematoporphyrin Derivative Phase 3,Phase 2,Phase 1
48 Hematoporphyrins Phase 3,Phase 2,Phase 1
49 Adjuvants, Anesthesia Phase 3
50 Analgesics, Opioid Phase 3

Interventional clinical trials:

(show top 50) (show all 271)
id Name Status NCT ID Phase
1 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00002569 Phase 3
3 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3
4 Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma Completed NCT00002840 Phase 3
5 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3
6 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
7 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3
8 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3
9 Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3
10 Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Recruiting NCT00978458 Phase 3
11 Fluorescence-guided Surgery for Low- and High-grade Gliomas Recruiting NCT01502280 Phase 3
12 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Active, not recruiting NCT00004259 Phase 3
13 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Active, not recruiting NCT01346267 Phase 3
14 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
15 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Active, not recruiting NCT00085202 Phase 3
16 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3
17 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
18 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3
19 Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Unknown status NCT00047294 Phase 2
20 Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma Unknown status NCT00045110 Phase 1, Phase 2
21 Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma Unknown status NCT00003176 Phase 2
22 Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma Unknown status NCT00047281 Phase 2
23 Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma Unknown status NCT01026493 Phase 1, Phase 2
24 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2
25 Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas Completed NCT00003473 Phase 2
26 SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy Completed NCT00004868 Phase 1, Phase 2
27 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003731 Phase 2
28 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2
29 Topotecan in Treating Patients With Recurrent Brain Tumors Completed NCT00003372 Phase 2
30 Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse Completed NCT00003775 Phase 2
31 Fenretinide in Treating Patients With Recurrent Malignant Glioma Completed NCT00006080 Phase 2
32 Temozolomide in Treating Patients With Low-Grade Glioma Completed NCT00313729 Phase 2
33 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2
34 Irinotecan in Treating Patients With Recurrent Glioma Completed NCT00003134 Phase 2
35 Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma Completed NCT00003616 Phase 1, Phase 2
36 Temozolomide in Treating Patients With Progressive Low-Grade Glioma Completed NCT00003466 Phase 2
37 Sunitinib in Treating Patients With Recurrent Malignant Gliomas Completed NCT00499473 Phase 2
38 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2
39 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2
40 Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma Completed NCT00124657 Phase 1, Phase 2
41 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2
42 Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma Completed NCT00003467 Phase 2
43 Immunotoxin Therapy in Treating Patients With Malignant Glioma Completed NCT00006268 Phase 1, Phase 2
44 Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma Completed NCT00005081 Phase 2
45 Temozolomide in Treating Patients With Recurrent High-Grade Glioma Completed NCT00619112 Phase 2
46 Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma Completed NCT00352521 Phase 2
47 ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma Completed NCT00352313 Phase 1, Phase 2
48 Study of Capecitabine to Treat Recurrent High Grade Gliomas Completed NCT00717197 Phase 2
49 Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma Completed NCT00795665 Phase 2
50 Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma Completed NCT00079092 Phase 2

Search NIH Clinical Center for Mixed Glioma

Cochrane evidence based reviews: glioma

Genetic Tests for Mixed Glioma

Anatomical Context for Mixed Glioma

MalaCards organs/tissues related to Mixed Glioma:

39
Brain, Endothelial, Cerebellum

Publications for Mixed Glioma

Articles related to Mixed Glioma:

(show all 13)
id Title Authors Year
1
Mixed Glioma (Oligoastrocytoma) in the Brain ofA an African Hedgehog (Atelerix albiventris). ( 25172052 )
2014
2
Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true "oligoastrocytoma"? ( 25359109 )
2014
3
Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience. ( 17252186 )
2007
4
Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. ( 12889176 )
2003
5
Long-term outcome of low-grade oligodendroglioma and mixed glioma. ( 10751254 )
2000
6
Can experimental models of rodent implantation glioma be improved? A study of pure and mixed glioma cell line tumours. ( 9524101 )
1998
7
Exophytic malignant brainstem mixed glioma in an adult: a case report. ( 9524090 )
1998
8
Combined occurrence of third ventricular germinoma and hypothalamic mixed glioma. ( 3713193 )
1986
9
Spontaneous hemorrhage in a mixed glioma of the cerebellum: case report. ( 3748360 )
1986
10
Mixed glioma of the cerebellopontine angle. ( 3878094 )
1985
11
Immunohistochemical detection of factor VIII/von Willebrand factor in hyperplastic endothelial cells in glioblastoma multiforme and mixed glioma-sarcoma. ( 6286891 )
1982
12
Mixed glioma and rhabdomyosarcoma in brain of a wild deer. ( 929897 )
1977
13
Mixed glioma, multiple sclerosis, and Charcot-Marie-Tooth disease. ( 5050901 )
1972

Variations for Mixed Glioma

Expression for Mixed Glioma

Search GEO for disease gene expression data for Mixed Glioma.

Pathways for Mixed Glioma

Pathways related to Mixed Glioma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.66 PDGFRA TP53
2 10.61 IDH1 PDGFRA TP53

GO Terms for Mixed Glioma

Biological processes related to Mixed Glioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-mediated signaling GO:0048015 8.8 AGO2 PDGFRA TP53

Sources for Mixed Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....